AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-28	JP¥36.00	0.00%	1,406,500
26-09-25	JP¥36.00	0.00%	835,900

Delayed Quote Japan Exchange

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Delayed Japan Exchange 02:30:00 2026-09-28 EDT			5-day change	1st Jan Change
36.00 ^JPY	0.00%		0.00%	-40.98%

08-30	AnGes, Inc. announced that it has received ¥2.022905015 billion in funding from Growth Partners Co., Ltd.	CI
08-14	AnGes, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	14.36B 91.22M 80.23M 75.86M 68.81M 129M 8.76B 130M 908M 351M 4.47B 342M 335M	P/E 2024	-0.44x	P/E 2025	-4.22x
Enterprise Value	12.53B 79.61M 70.01M 66.21M 60.05M 113M 7.64B 113M 793M 306M 3.9B 299M 292M	EV / Sales 2024	21.1x	EV / Sales 2025	25x
Free-Float	92.28%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Japan Exchange	4563	Delayed
Deutsche Boerse AG	AJW	Delayed
Börse Stuttgart	AJW	Delayed
Tradegate	AJW	Real-time
Boerse Muenchen	AJW	Real-time

08-30	AnGes, Inc. announced that it has received ¥2.022905015 billion in funding from Growth Partners Co., Ltd.	CI
08-14	AnGes, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	AnGes, Inc. announced that it expects to receive ¥2.022905 billion in funding from Growth Partners Co., Ltd.	CI
08-13	AnGes, Inc. announced that it expects to receive ¥2.022905015 billion in funding from Growth Partners Co., Ltd.	CI
05-07	AnGes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-24	AnGes, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-24	Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis Patients	CI
03-04	Vasomune Therapeutics, Inc., and AnGes, Inc., announce US FDA clearance of investigational new drug (IND) application for pegevongitide (AV-001) treatment in resuscitation of severely burned patients	RE
11-25	Anges and Vasomune Therapeutics enter agreement for AV-001	RE
11-25	Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications	CI
11-06	AnGes, Inc. announced that it expects to receive ¥31.833813 million in funding	CI
25-09-03	Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients	CI
25-03-30	AnGes, Inc. Auditor Raises 'Going Concern' Doubt	CI

AnGes, Inc. Stock

Stocks

4563

JP3127700007

Biotechnology & Medical Research

Valuation: AnGes, Inc.

Chart: AnGes, Inc.

Latest news: AnGes, Inc.

Press Releases: AnGes, Inc.

News in other languages: AnGes, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: AnGes, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-14	AnGes : Consolidated Financial Report for the Second Quarter 2026	PU
07-22	Vasomune Therapeutics to Present on Vascular Leak in Combat-Relevant Injury at the 2026 Military Health System Research Symposium	AQ
05-14	AnGes : Notice Regarding the Conduct of a Type B CMC Meeting for the HGF gene therapy product	PU
05-08	AnGes : Financial Results Summary of 1st Quarter 2026	PU
05-08	AnGes : Consolidated Financial Report for the First Quarter 2026	PU

23-08-07	Tupperware Brands Corporation: le plastique, c'est fantastique
23-08-07	Tupperware Brands Corporation: plastic is fantastic
23-08-04	Tupperware Brands Corporation: El plástico es fantástico
23-08-04	Tupperware Brands Corporation : Le plastique, c'est fantastique
23-05-15	Divisas: ¿el rebote del gato muerto?

Current month	-7.69%
1 month	-7.69%
3 months	-20.00%
6 months	-40.00%
Current year	-40.98%

1 week	35	37
1 month	34	41
Current year	34	71
1 year	34	93
3 years	34	120
5 years	34	711
10 years	34	2,492

Manager	Title	Age	Since
Ei Yamada PSD	President	76	2002-08-31
Naoya Sato DFI	Director of Finance/CFO	66	2024-07-31
Yuka Murakami IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Ei Yamada BRD	Director/Board Member	76	2001-07-31
Naoya Sato BRD	Director/Board Member	66	2022-02-28
Akira Kondoh BRD	Director/Board Member	81	2026-02-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANGES, INC.	0.00%	0.00%	-56.63%	-62.50%	91.24M
WUXI APPTEC CO., LTD.	-0.37%	+1.12%	+57.21%	+84.56%	72.26B
ARGENX SE	-0.07%	-3.08%	+37.74%	+84.21%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+0.75%	+6.06%	+36.71%	+19.87%	27.73B
INSMED INCORPORATED	-0.14%	-1.94%	-14.13%	+354.32%	25.73B
BIONTECH SE	+0.57%	+3.14%	+1.02%	-3.92%	24.75B
GENMAB A/S	+1.10%	+1.86%	+25.07%	-8.51%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	-2.12%	+150.24%	+323.16%	15.06B
EXELIXIS, INC.	+0.36%	+0.02%	+49.51%	+163.05%	14.41B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.53%	-1.39%	-6.38%	+469.36%	14.23B
Average	-0.20%	-0.12%	+28.04%	+142.36%	27.52B
Weighted average by Cap.	-0.12%	-1.05%	+38.10%	+125.23%

	2024	2025
Net sales	643M 4.09M 3.59M 3.4M 3.08M 5.79M 392M 5.82M 40.68M 15.71M 200M 15.34M 15M	874M 5.55M 4.88M 4.62M 4.19M 7.87M 533M 7.91M 55.29M 21.35M 272M 20.85M 20.4M
Net income	-28.13B -179M -157M -149M -135M -253M -17.15B -255M -1.78B -687M -8.75B -671M -656M	-5.12B -32.55M -28.63M -27.07M -24.55M -46.11M -3.12B -46.38M -324M -125M -1.59B -122M -120M
Net Debt	-1.44B -9.12M -8.02M -7.59M -6.88M -12.92M -876M -13M -90.85M -35.09M -447M -34.25M -33.51M	-1.83B -11.61M -10.21M -9.66M -8.76M -16.45M -1.11B -16.55M -116M -44.66M -569M -43.6M -42.66M